Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

7 Apr 2010

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company has been selected to present key efficacy data at the upcoming American Academy of Neurology (AAN) 62nd Annual Meeting to be held in Toronto, Canada.

7 Apr 2010

AbleNet adds Madentec's entire line of assistive technology solutions to product portfolio

AbleNet, Inc. announces the agreement with Madentec Limited of Edmonton, Alberta, Canada for the exclusive global rights to manufacture and sell their entire line of assistive technology solutions. This adds a broad portfolio of proven devices to the AbleNet computer access products. Madentec will continue to own the products and provide engineering development support, which has been their core strength.

7 Apr 2010

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.

6 Apr 2010

Dalfampridine drug for multiple sclerosis now available in the U.S.

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

6 Apr 2010

Free online training program for saving individuals with disabilities during fire emergencies

United Spinal Association has developed a free online training program designed to save the lives of individuals with disabilities and mobility impairments during fire emergencies.

5 Apr 2010

Disability Leadership and Policy Summit to be hosted in Philadelphia, Pennsylvania

United Spinal Association will host its inaugural Disability Leadership and Policy Summit on April 15th in Philadelphia, commemorating the 20th Anniversary of the Americans with Disabilities Act, which was signed into law on July 26, 1990 and prohibits discrimination based on disability. The law was amended in 2008 to offer more protection to disabled workers.

5 Apr 2010

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the company will participate in a panel discussion on Personalized Medicine for the Treatment of Multiple Sclerosis on April 7, 2010.

5 Apr 2010

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

A recent development can raise the hopes of many sufferers of Multiple Sclerosis (MS) – a dreaded, debilitating, fatal nerve disorder. Charity worker Sami Chugg, 45, claims to have overcome her condition after being stung by bees.

5 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

A new study reveals an exciting potential benefit of the rapidly accumulating databases of health care information, the ability to make unprecedented links between genomic data and clinical medicine. The research, published by Cell Press in the April issue of the American Journal of Human Genetics, supports the idea that large scale DNA databanks linked to electronic medical record (EMR) systems provide a valuable platform for discovering, assessing and validating associations between genes and diseases.

2 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

The American Academy of Neurology (AAN) is awarding the 2010 Dreifuss-Penry Epilepsy Award to Martin J. Gallagher MD, PhD, with Vanderbilt University School of Medicine. Gallagher will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

The American Academy of Neurology (AAN) is awarding the 2010 Sheila Essey Award-An Award for ALS Research to Clive Svendsen, PhD, with the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, CA. Svendsen will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

2010 John Dystel Prize for Multiple Sclerosis Research awarded to Yale University researcher

The American Academy of Neurology is awarding the 2010 John Dystel Prize for Multiple Sclerosis Research to David A. Hafler, MD, with Yale University. Hafler will receive the award during the AAN's 62nd Annual Meeting in Toronto, held April 10 through April 17, 2010.

31 Mar 2010

WOCN Society launches campaign to raise awareness about benefits of specialized care

Patients and families who are dealing with conditions such as non-healing wounds, bedsores, bladder and bowel incontinence and ostomy-related issues contend with physical symptoms, as well as social and emotional side effects. The impact on patients and families can exact an enormous toll. The Wound Ostomy & Continence Nurses Society is launching a campaign to raise awareness about the benefits of specialized care.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancer

Opexa Therapeutics to present data from Phase 2b TERMS clinical trial for Tovaxin at 62nd AAN meeting

AbleNet adds Madentec's entire line of assistive technology solutions to product portfolio

New study shows utility of Chronix Biomedical's serum DNA tests in MS

Dalfampridine drug for multiple sclerosis now available in the U.S.

Free online training program for saving individuals with disabilities during fire emergencies

Disability Leadership and Policy Summit to be hosted in Philadelphia, Pennsylvania

Opexa Therapeutics to discuss on personalized medicine for treatment of MS

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

New report questions the kinetics of T cell receptors

Clinical utility and pharmacological action of MN-166 in treatment of MS

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

AAN awards 2010 Dreifuss-Penry Epilepsy Award to Vanderbilt University School of Medicine researcher

AAN awards Cedars-Sinai researcher 2010 Sheila Essey Award for ALS research

2010 John Dystel Prize for Multiple Sclerosis Research awarded to Yale University researcher

WOCN Society launches campaign to raise awareness about benefits of specialized care

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in